Valuation : Inotiv, Inc.

Market Cap 387K 333K 313K 286K 533K 36.71M 536K 3.71M 1.44M 18.77M 1.45M 1.42M 59.72M P/E 2024
-0.41x
P/E 2025 -0.69x
Enterprise Value 438M 377M 354M 323M 603M 41.52B 606M 4.2B 1.62B 21.22B 1.64B 1.61B 67.53B EV / Sales 2024
0.95x
EV / Sales 2025 0.95x
Free-Float
93.37%
Yield 2024 *
-
Yield 2025 -
1 day-26.00%
3 months-90.01%
6 months-96.99%
Current year-98.03%
Current year 0.01
Extreme 0.007
0.65
1 year 0.01
Extreme 0.007
1.62
3 years 0.01
Extreme 0.007
11.42
5 years 0.01
Extreme 0.007
60.66
10 years 0.01
Extreme 0.007
60.66
Manager TitleAgeSince
Chief Executive Officer 67 12/01/2019
Director of Finance/CFO 61 06/03/2020
Chief Operating Officer 60 15/02/2021
Date Insider Type Main position Quantity % Market Cap. Importance
7/19/26 A Others

Chief Executive Officer

-1,361,215 3.9017%
7/19/26 A Others

Director

-729,626 2.0913%
7/19/26 A Others

Chief Financial Officer

-139,616 0.4002%
Change 5-day change 1-year change 3-year change Capi.($)
-26.00%-.--%-99.31%-99.66% 387K
-2.68%-7.47%-5.03%+10.80% 48.01B
-1.29%-1.22%+404.92%+545.45% 44.44B
-3.20%+0.33%+38.11%+21.39% 42.67B
-1.89%-2.00%+1.45%+82.46% 39.96B
-1.72%-2.61%+13.09%+42.33% 32.75B
-0.17%+3.78% - - 17.74B
-0.07%+1.32%+20.08%+117.95% 16.49B
+0.39%-1.70%+11.85%+32.04% 14.38B
-2.68%-0.56%+73.31%+40.56% 13.4B
Average -3.92%-4.27%+50.94%+88.15% 26.98B
Weighted average by Cap. -1.80%-1.05%+84.68%+132.09%

Financials

2024 2025
Net sales 491M 422M 397M 362M 676M 46.52B 680M 4.7B 1.82B 23.78B 1.84B 1.8B 75.67B 513M 441M 415M 379M 707M 48.64B 710M 4.92B 1.9B 24.86B 1.93B 1.88B 79.11B
Net income -108M -93.24M -87.72M -80.05M -149M -10.28B -150M -1.04B -402M -5.25B -407M -398M -16.72B -68.62M -59M -55.51M -50.66M -94.54M -6.51B -95.03M -658M -254M -3.33B -258M -252M -10.58B
Net Debt 424M 364M 343M 313M 584M 40.17B 587M 4.06B 1.57B 20.53B 1.59B 1.56B 65.33B 438M 376M 354M 323M 603M 41.48B 606M 4.19B 1.62B 21.2B 1.64B 1.61B 67.47B
Logo Inotiv, Inc.
Inotiv, Inc. is a contract research company engaged in providing nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries and selling a range of research-quality animals and diets to the same industries, as well as academia and government clients. Its products and services focus on bringing new drugs and medical devices through the discovery and preclinical phases of development. It operates through two segments: Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through DSA segment, it supports the discovery, nonclinical development and clinical development needs of researchers and clinicians for primarily small molecule drug candidates, as well as biotherapeutics and biomedical devices. Through RMS segment, it offers access to a range of small and large research models for basic research and drug discovery and development, as well as specialized models for specific diseases and therapeutic areas.
Employees
1,996
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. NOTV Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!